Bayer and GSK have a Zacks Rank #2 (Buy) each, while Novo Nordisk, AbbVie, and Merck carry a Zacks Rank of 3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GSK is paying $1.2 billion upfront to Boston Pharmaceuticals for an experimental drug to treat MASH. Eli Lilly plans to expand Purdue University collaboration with up to a $250 million investment ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

currently with Boston Pharmaceuticals and Pfizer, which also involve 4-1BB bispecific proteins. Pfizer is developing SGN-BB228, a CD228/4-1BB candidate it inherited as part of its takeover of ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, have announced that they have ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

The company, founded in 2019 by quantum physics researcher Maximilien Levesque and Emmanuelle Martiano, a former consultant ...